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 Introduction 
 Back in 2003, Brazil’s and Mozambique’s presidents, Luiz Inácio Lula da 
Silva and Joaquim Chissano, agreed to set up the first pharmaceutical 
factory in Mozambique, to be entirely owned by the national govern-
ment. The project – widely known as the Brazil-Mozambican anti-retro-
viral factory because of its commitment to produce AIDS drugs – still 
represents the single most expensive and eye-catching project of Brazil’s 
South-South cooperation programme in the health sector. 
 Part I of this book examines the complexities of African pharmaceu-
tical markets and some practical aspects of setting up and developing 
pharmaceutical industries in the subcontinent. This chapter’s contribu-
tion is to present the experience of establishing a pharmaceutical factory 
in Mozambique through industrial and official development collabora-
tion between two national governments. Uniquely, this is a case study 
of an attempt to kick-start, through an innovative South-South part-
nership, pharmaceutical production in a country that previously had 
none. This chapter therefore discusses an experience sharply distinct 
from most of the countries’ experiences discussed in the book, since 
they have pharmaceutical industries dating back to the 1950s, and with 
substantial numbers of firms in their industries. 
 This chapter draws on multiple sources such as official technical coop-
eration documents and the published literature on the subject, as well 
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as on the authors’ direct experience of the Mozambican pharmaceu-
tical markets, of Brazil’s development cooperation programme and of 
the factory’s implementation project. It aims chiefly to discuss whether 
foreign lessons about the development of the pharmaceutical sectors 
can be learned for African countries, and the extent to which similar 
experiences of industrialization and health policy development can be 
exported from Brazil to the complex African environment. Two main 
contributions to the making medicines in Africa debate emerge from the 
analysis of this case study: one is the absolutely key role of the innova-
tive South-South collaboration to the nascent pharmaceutical industry 
in Mozambique in terms of both financial subsidy and technical support. 
The other is that, while the technical collaboration with Brazil remains 
highly positive, the link to the market in Mozambique seems to have 
been a major problem, as the health-industry link so fundamental in the 
Brazilian pharmaceutical development experience seems to have worked 
less well here, at least in the early years of the project. 
 After a description of the evolution of the cooperation project and 
of the collaboration between the two countries to set up a factory in 
Mozambique, this chapter presents details of the technical investment 
needed to start such a complex enterprise in a country with a less-than-
ideal business environment. The crucial link between the factory and 
the local as well as regional pharmaceutical markets is then analysed. 
The chapter ends with a discussion of the issues still hampering the 
development of the factory in Mozambique, and of the insight to be 
gained from such an experience, including insights for those countries 
in the subcontinent with a rather more established pharmaceutical 
industry. 
 The Brazil-supported pharmaceutical factory in 
Mozambique 
 Official reports show that back in 2003, the initiative to set up a phar-
maceutical factory in Mozambique originally had the following stated 
objectives. It aimed to secure the supply of anti-retroviral medicines 
(ARVs) for HIV/AIDS treatment in the country, and to jump-start phar-
maceutical generics’ manufacturing in Mozambique, enabling the fulfil-
ment of the objectives of the national primary care and pharmaceutical 
policies. It also aimed to reduce the country’s dependence on pharma-
ceutical donations and imports and to contribute to the creation of local 
capacity for pharmaceutical production and industrial management (de 
Oliveira, 2013). 
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 Following an informal agreement between the two presidents, diplo-
matic and international cooperation efforts were stepped up from both 
the Brazilian and Mozambican governments to iron out the details of 
the project from 2003 onwards. Figure 5.1 summarizes the long timeline 
of the project from its inception to 2014. 
 The Oswaldo Cruz Foundation (Fiocruz) – Brazil’s leading public health 
institution (Roa and Baptista e Silva, 2015) – was appointed in 2004 to 
conduct the factory’s feasibility study. This was completed and approved 
three years later.  Farmanguinhos – Fiocruz’s pharmaceutical arm, and a 
key instrumental actor in Brazil’s national pharmaceutical policy – 
was charged with the pharmaceutical technological transfer, technical 
training and the wider project implementation. These two institutions 
are directly linked to the Brazilian Ministry of Health and have been 
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 Figure 5.1  Timelines for the implementation of the factory project 
 Source : drawn by the authors. 
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pharmaceutical regulation as well as of the pharmaceutical market in 
Brazil (Flynn, 2008). (Their role is discussed further in Chapter 9). These 
institutions’ early involvement in the factory project in Mozambique 
was considered instrumental in seeking to replicate that experience back 
home. 
 Meanwhile, in the field, a number of cooperation agreements and 
spending authorizations had to be sought by both the Mozambican 
and Brazilian sides, as the project was to be funded through multiple 
sources. The process was lengthy. VALE S.A. – Brazil’s largest mining 
company with ongoing operations in Mozambique – was also recruited 
by President Lula to support the national government in financing the 
factory’s infrastructure works, which were only finalized in 2012. In the 
same year, the majority of the pharmaceutical equipment was procured 
in the international market, donated by  Farmanguinhos , and shipped 
to the future factory venue. The government of Mozambique recruited 
the first 15 local staff in the same year, and  Farmanguinhos donated the 
pharmaceutical production technology files and provided the tech-
nical assistance required to start production of Nevirapine, Lamivudine, 
Captopril and Hydrochlorothiazide in 2013 (Russo et al., 2014). 
 In 2008, the enterprise was officially registered as Mozambique 
Pharmaceuticals Ltd ( Sociedade  Moçambicana de  Medicamentos, SMM), as 
it planned to extend production beyond anti-retroviral drugs. SMM is 
owned by the government of Mozambique’s State Assets Management 
Institute (IGEPE), which appoints the executive director and chair of its 
administrative board from candidates put forward by the Mozambican 
Ministry of Health (MISAU). In addition to the short-term Brazilian 
technical assistance necessary for training and setting up operations, 
four full-time Brazilian consultants in pharmaceutical manufacturing, 
quality assurance, technical engineering and maintenance have been 
appointed for the coming years, with the objective of steering the 
factory towards sustainable production and WHO Quality Certification 
(Russo et al., 2014). 
 According to official documents (de Oliveira, 2012), the government 
of Brazil (GoB) originally agreed to take responsibility for the project’s 
staff training, for procuring equipment and raw materials, for providing 
technical assistance and for designing the factory and managing the 
project. Meanwhile the government of Mozambique (GoM) was to be 
responsible for purchasing the physical infrastructure for the factory, 
for undertaking rehabilitation works, for funding the factory’s recur-
rent expenditures and for buying the bulk of the factory’s pharmaceu-
tical output. The first three-year cooperation agreement was signed in 
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2011. Extensions of the original 2011 agreement were to be negotiated 
every three years through official Complementary Agreements ( Ajustes 
 complementares ). 
 In 2014, procurement contracts were signed by MISAU for the 
acquisition of locally produced hospital serum bags and imported but 
locally packaged generic drugs from the factory. Although disruptions 
were experienced in 2014 in the production lines, a fresh cooperation 
agreement was signed the same year to extend Brazil’s support to the 
factory until 2017. Towards the end of the same year, following a visit of 
Mozambican officials to the Brazilian Ministry of Health and Ministry 
of Foreign Trade, Industry and Development, a decision was taken by 
IGEPE – the institution in responsible for the factory – to seek capital 
to finance the factory from the Mozambican banking sector, and at the 
time of writing this seems to be the path identified for the development 
of the project in the near future (Figure 5.1). In the process of devel-
oping the factory, more than ten years and three presidential terms have 
elapsed both in Mozambique and Brazil, and administrative, political 
and foreign affairs details have had to be ironed out across two countries 
and four different political administrations. 
 The new pharmaceutical factory is located in Matola City within 
Mozambique’s capital’s metropolitan outskirts, on a 20,000-square-
metres allotment close to the capital’s commercial port and to the 
South African border. The factory currently engages both in secondary 
and tertiary pharmaceutical production. That is, it produces its own 
formulations from imported active pharmaceutical ingredients (APIs) 
and raw materials, as well as packing imported finished formulations. 
Twenty-one generic drugs are planned to be produced in the next two 
years, including ARVs (Nevirapine, Zidovudine and Lamivudine combi-
nations), hypertension drugs (Captopryl and Propanolol) and a list 
of antibiotics, antimycotics and anti-diabetic compounds specifically 
requested by the MISAU as currently in wide use in the country’s public 
National Health Service (NHS). Such a list can be expanded on demand 
to include generic drugs to meet the WHO requirements for ARV treat-
ment and generic formulation to be sold by third parties. All the formu-
lations (pharmaceutical dossiers) belong to  Farmanguinhos and are 
transferred for free to MISAU. A laboratory for the control of medicine 
quality has been already established, equipped to test drugs for efficacy 
and safety. When fully functional, the laboratory will be capable of 
providing information on the quality of all the drugs imported into the 
country and of contributing to the development of new drug testing 
methodologies. 
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 The technical investment 
 So far the factory’s overall set-up costs have been estimated at US$ 
39.6 million (de Oliveira, 2013). Capital investment (land, infrastruc-
tures, machinery and implementation of production lines) amounted to 
approximately 46.5% of overall expenditures and pledged funds, while 
technological transfers and technical assistance represented a substan-
tial cost item (13.0%), including the value of compounds dossiers for the 
21 generic drugs, as well as personnel costs for the expatriate staff who 
helped setting up the operations. Running costs for the first year (API 
procurement, training and maintenance) represented 23.7% of present 
and future expenditures (Table 5. 1). 
 Although the Brazilian government funded the majority of the 
project’s set up costs (62.7%), the government of Mozambique contrib-
uted through buying up land and some existing infrastructure for the 
establishment of the factory, while a donation from VALE, a Brazilian 
mining company operating in Mozambique, supported personnel and 
infrastructure expenditures (Table 5.1). 
 As Brazil still lacks a comprehensive legal framework to provide funds 
and procure goods for its international cooperation programme (Cabral, 
Russo and Weinstock, 2014), funds for the project had to be channelled 
through the implementing public institutions linked to the Brazilian 
Ministry of Health – Fiocruz, Fiotec and Farmanguinhos – and through 
the Brazilian Development Cooperation Agency (ABC), linked to the 
Ministry of Foreign Affairs ( Itamaraty ). On the Mozambican side, the 
costly acquisition of the infrastructure from a former hospital serum 
bags factory ( Final  Farmacêutica) was directly managed by the govern-
ment, while IGEPE funded the capital rehabilitation and maintenance 
costs. The donation to the venture by VALE S.A. was expressly solicited 
by the government of Brazil and channelled through the government 
of Mozambique Treasury to set up the factory’s early production lines 
and pay for some Brazilian personnel as part of the running costs. With 
the extension of the cooperation agreement to 2017, both governments 
agreed to further the funding of the project. 
 Although according to the business plan the factory would require 88 
full-time staff to manufacture at full capacity (24 for direct production, 4 
for quality-control-related services, and 18 for management and admin-
istration), at the time of writing only 55 had been recruited, and a team 
of 8 Brazilian technical assistants based in Maputo were still providing 
key management and technical expertise for the factory’s operations. 
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technical personnel as well as senior managers for the new factory had 
to be either summoned from the Brazilian public sector or recruited in 
the local market and provided for extra training abroad. 
 In terms of technological transfer, until March 2015,  Farmanguinhos 
had donated for free 10 out of 21 technological dossiers for the produc-
tion of specific pharmaceuticals, to include results from pharmaceutical 
equivalence tests, quality control procedures for APIs and other ingredi-
ents, manufacturing process specifications and test failure reports. The 
next steps for technological production are still under way and include:
 adaptation of the Brazilian dossiers to the MISAU’s specifications;  ●
 training local personnel to the local production of the pharmaceu- ●
tical dossier; 
 assisting production for the drugs’ first three pilot batches, following  ●
production as well as commercialization of the products; 
 establishing a pharmacovigilance system.  ●
 In terms of pharmaceutical production equipment, 18 high-tech pieces 
have been procured internationally by  Fiocruz/ Farmanguinhos and 
donated by Brazilian cooperation. This included main production line 
equipment such as compression, coating and blender machines, packing 
equipment – blisters, labelling and capping machines – as well as quality 
and in-process control equipment – tablets’ hardness and dissolution 
testers, chromatography and centrifuges. Given the total absence of 
up-to-date manufacturing machinery in the infrastructures inherited 
from  Final  Farmacêutica , basic non-specific equipment such as water 
purification machines also had to be brought in. 
 The machines presently installed in the factory in Maputo have an 
estimated market value of US$4 million, with an additional list of equip-
ment worth approximately US$1 million to be procured and bought 
by 2017. All the machines were purchased by  Farmanguinhos/ Fiocruz 
through international tenders and donated to the government of 
Mozambique, including installation services and personnel training for 
its use and maintenance. SMM technical personnel were all trained in 
Brazil on the use of the specific machines, and on-site ongoing technical 
assistance is provided for specific manufacturing. 
 The company and the market 
 This section details a key – and often overlooked – aspect of the Brazil-
Mozambique collaboration to produce pharmaceuticals: the link to 
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the market. A feasibility study was conducted in 2007 looking at the 
likely costs of setting up the factory in Maputo and its specific produc-
tion capacity for ARVs, but it failed to analyse the market conditions 
in Mozambique and in the wider Sub-Saharan region (Fiotec/Fiocruz, 
2007). 
 Mozambique’s pharmaceutical policy in the 1970s and 1980s focussed 
on procuring and using generic drugs, to extract the best possible value 
from its drugs budget (Barker, 1983). However, as Mozambique became 
after Independence one of the world’s largest recipients of health-
aid funds, international finance for drugs began to be handled, first 
through an externally managed Drugs Common Fund (Pavignani and 
Durão, 1999), and subsequently through an MoH-managed Sector Wide 
Approach common fund agreement (PROSAUDE). Currently, with the 
global push for AIDS fight and the introduction of anti-retroviral treat-
ment (ART) in 2003, the country is enjoying a considerable injection 
of AIDS funds, with anti-retroviral drugs procured in the international 
market by organizations such as the Global Fund, the World Bank and 
USAID. 
 In 2012, the national drugs market in Mozambique was estimated 
to be worth approximately US$140 million in terms of the value of 
drugs imported (COWI, 2012), which represented a drugs expenditure 
of US$5.55 per capita. Eighty-five per cent of the total market value 
was represented by public sector imports, mostly funded by external 
funds and donations, some of them managed by the local Ministry of 
Health through the sector budget support fund, PROSAUDE (CMAM, 
2011). In recent years public drugs expenditures have gone from 
US$78 million in 2004 to US$122 million in 2012 (Table 5.2), the 
increase being driven by in-kind AIDS drugs donations that rose from 
the original US$4 million to the current US$49 million in eight years 
(COWI, 2012). 
 As shown in Table 5.2, AIDS drugs represent the largest single item of 
the national public pharmaceutical expenditures, and enter the country 
exclusively as in-kind donations procured and managed directly by 
foreign organizations. Public funds pay for roughly a quarter of the 
overall public sector drug expenditures, with North-America-based 
organizations (USAID, Supply Management Systems and the Clinton 
Health Access Initiative) contributing to purchase 67% of all the public 
sector drugs procured in the country. In this respect, the local funding 
environment appears still to represent a critical limitation for phar-
maceutical production in Mozambique. Given the typical consumer’s 
limited ability to pay, and the relatively small size of the local private 
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sector, selling to the public sector is obviously the only way for local 
producers to go to scale and access a local market worth in excess of 
US$140 million. However, the lack of flexibility of the international 
drugs financing environment is pointed to by many as a key limiting 
factor for the development of local production of pharmaceuticals in 
the country; even if locally produced drugs were made available at 
competitive prices, the manner in which external funds for AIDS drugs 
are currently regulated would stand in the way of procuring, or offering 
preferential procurement terms to buy, locally produced drugs. As a side 
effect, free internationally procured ARVs also end up crowding out the 
local private sector, which is traditionally a key customer for locally 
produced goods (Herzer and Grimm, 2012; Rajan and Subramanian, 
2011). 
 Little consolidated data exist about the private pharmaceutical market 
in Mozambique. Some estimates put it at approximately US$20 million, 
calculated on the basis of the drugs value declared on the import 
documents submitted to the pharmaceutical department in 2012 
(COWI, 2012). Although 54 private importers are officially registered 
 Table 5.2  Public sector drug import value, by source and type of health 
programme (2012 US$ ) 
 Health programme 
and associated drugs 




pool and state 
budget) 
 In-kind 
donations  Total 
Hospital drugs 11,861,471 1,200,883 13,062,354
Primary care drug kits 8,708,824 0 8,708,824
Community health 3,870,588 7,217,900 11,088,488
STD and HIV-SIDA 0 48,750,977 48,750,977
TB 0 249,550 249,550
Malaria 0 24,124,599 24,124,599
Blood banks 967,647 0 967,647
Oral health 290,294 0 290,294
Surgical supplies 10,111,912 0 10,111,912
Laboratory supplies 2,497,000 0 2,497,000
Imaging devices and 
supplies
1,741,765 0 1,741,765
Total 40,049,500 81,543,908 121,593,408
 Source : CMAM, 2012. 
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in Mozambique, a 2010 study found that the private sector is highly 
concentrated, with the four largest firms handling more than 50% of the 
drugs imported (Russo and McPake, 2010). 
 As for the regional market, according to some industry pundits (IMS, 
2012), with its 10.6% yearly growth rate by volume, Africa is the world’s 
fastest-growing pharmaceutical market after Asia, and is estimated to 
reach a value of US$30 billion next year. With specific reference to the 
ARVs market in the Southern African Development Community, the 
SMM business plan estimated in 2012 that a sufficiently homogeneous 
regional demand for ARVs existed for SMM to serve. Previous studies 
of the regional market (COWI, 2012) suggested that across the neigh-
bouring countries of Mozambique, Tanzania, Zambia and Zimbabwe, 
AIDS treatment lines were relatively similar and reliant on standard 
Lamivudine-Zidovudine-Nevirapine combinations. This would have 
implied access to sizeable market for HIV/AIDS drugs of approximately 
6 million treatment doses per year across the four countries. However, 
there is little recognition in SMM’s viability study and subsequent busi-
ness plans of the complexity of those markets, of the possible regional 
and international competition to be faced, as well as of their regulation 
and of the role played by national governments in supporting the local 
industry. 
 Currently, SMM’s business plan expects to sell its products in the 
Mozambican market in the short term, particularly to the NHS. It aims to 
sell into the regional pharmaceutical market only in the medium term, 
once the required certifications are obtained to allow the firm to compete 
in international tenders (COWI, 2012; SMM and Farmanguinhos, 2013). 
SMM unit prices, listed in Table 5.3, reflect the initial production costs 
calculated on the basis of APIs imported from Brazil. As production goes 
to scale and APIs are bought in from the global competitive market, SMM 
is projecting lower selling prices reflecting the lower API costs. SMM also 
enjoys most of the standard preferential policy interventions already 
adopted in the East Africa Community: an ad hoc tax exemption regula-
tion on imported APIs and other manufacturing product and a prefer-
ential buying regime from the government, according to which, when 
procuring drugs for the National Health care Service, the National Drugs 
Acquisition Agency is required to give preference to locally produced 
drugs as long they are no more than 15% more expensive than the prod-
ucts of their international competitors. 
 The prices listed in Table 5.3 represent SMM’s factory gate selling prices 
for public procurement; a comparison with the Management Science 
for Health international median reference prices for procurement is 
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also shown. It is worth noting that although in the same price range, 
SMM prices for ARVs, particularly those involving Lamivudine, appear 
to compare less favourably with international reference prices than do 
those for the other generic drugs (Table 5.3). 
 The factory’s business plan predicted wholesale selling price levels at 
which the factory would break even, on the basis of the cost structure 
model used for the production of ARVs in Brazil’s state pharmaceutical 
factories adapted to the Mozambican context (Pinheiro et al., 2006). 
Although SMM drugs face higher costs because of Mozambique’s burden-
some import duties on non-API production materials, as well as high 
maintenance costs, according to the factory’s business plan these will be 
offset by lower capital costs and smaller operating margins, typical of a 
state-owned company (MacDonald and Yamey, 2001). 




 SMM’s selling 





Amoxicillin caps 500 mg cx 
c/500
500 0.0502 0.0313
Glibenclamide tab 5 mg cx 
c/500
500 0.0035 0.0042
Hydrochlorothiazide tab 50 
mg cx c/500
500 0.0047 0.0050
Metronidazole tab 250 mg cx 
c/1000
1000 0.0116 0.0061
Prednisone tab 5 mg cx c/500 500 0.0077 0.0108
Lamivudine 150 mg 60 
tab – 3TC
60 0.1152 0.0508
Lamivudine 150  + Zidovudine 
300 mg 60 tab
60 0.4354 0.1714
Lamivudine 150 mg + 
Zidovudine 300 mg + 
Nevirapine 200 mg
60 0.2754 0.1654
Lamivudine 30 mg + 
Zidovudine 60 mg + 
Nevirapine 50 mg
60 0.1015 0.0726
Nevirapine 200 mg 60 
tab – AD
60 0.0849 0.0611
 Note: *Management Science for Health Drug Price Database. 
 Source : SMM. 
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 According to the factory’s business plan, SMM furthermore will be 
able to sell its products at prices comparable to those from the inter-
national market, thanks to savings in the initial investment in infra-
structures and equipment, donated by the Brazilian cooperation, and in 
national transport charges and taxes, which are particularly favourable 
to business in Mozambique, since the original tax rate on chemical prod-
ucts was scrapped. In comparison to the typical cost structure for ARVs 
(Pinheiro et al., 2006), SMM’s production costs will be largely driven 
by active pharmaceutical ingredients’ (APIs) import prices, and less by 
taxes, profit margins, research and development and local production 
mark-ups (SMM and Farmanguinhos, 2013). 
 The South–South collaboration in context 
 ‘Emerging donors’ and ‘South-South cooperation’ are terms usually refer-
ring to providers of development assistance and forms of cooperation 
that have recently become prominent in the international aid architec-
ture, due to a recent expansion in resources allocated to development 
cooperation with poor countries (Manning, 2006). Thanks to their recent 
economic growth, emerging economies like China, India and Brazil 
are boosting their cooperation programmes (Brautigam, 2009; Cabral, 
2010), and according to one estimate, the volume of aid from emerging 
donors reached between US$9.5 billion and US$12 billion in 2006, 
corresponding approximately to 8–10% of total aid flows. The recent 
literature on the subjects shows that some common features among 
these emerging aid players are discernible. One of the most salient is the 
emphasis on horizontal (South-South) cooperation between developing 
countries and the principle of non-interference in the internal affairs 
of recipient countries. Related to this aspect, emerging donors tend to 
have no policy-related conditionality, such as standards of governance 
and macroeconomic requirements, and fewer procedural conditions, 
such as counterpart funding or separate bank accounts, relative to tradi-
tional donors. More controversially, there is a more evident and openly 
acknowledged association between commercial interests, geo-strategic 
objectives and development cooperation than is the case for traditional 
donors (Kragelund, 2008). 
 Brazil’s overall cooperation programme is still relatively small, esti-
mated to be worth between US$350 million and US$1 billion per year, 
with a substantial component of support to international organizations 
and humanitarian assistance and a smaller proportion directed to tech-
nical cooperation projects (IPEA, 2011). South-South relations play an 
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important part in Brazil’s strategy of diversification of diplomatic and 
economic relations, and technical cooperation provides an expedient 
way of taking forward such an agenda. Brazil’s South-South technical 
cooperation programme has as key features the emphasis on exchange 
of experiences between equal partners (or ‘horizontal cooperation’, as 
it is usually referred to), respect for the partner country’s sovereignty 
and non-conditionality of support, with a dominant but not exclusive 
geographical focus on Latin American and Portuguese-speaking African 
countries and on the agriculture, education and health sectors (Cabral, 
Russo and Weinstock, 2014). 
 Government figures put the value of Brazilian technical health 
cooperation at approximately US$12 million between 2006 and 2009. 
However, recent independent reports estimated that Brazil spent 
between US$12 million and US$14 million in technical health coop-
eration projects in Portuguese-speaking African countries alone for the 
same period (Russo, Cabral and Ferrinho, 2013). Brazil’s health-sector-
specific characteristics and claimed principles suggest some important 
departures from the ways in which development cooperation has been 
traditionally practised. A key feature of Brazil’s cooperation is that it is 
openly driven by foreign policy goals, and development cooperation is 
seen as instrumental in promoting Brazil’s image and interests abroad. 
Brazil openly adopts the notion of ‘health diplomacy’ for its health 
projects (Roa and Baptista e Silva, 2015), implying that health devel-
opment cooperation can be informed by international health objec-
tives, following the recognition that national health problems need to 
be dealt with in the global health arena. Brazilian cooperation officials 
also dispute the use of the term ‘aid’ to define their work, as that would 
impose industrialised countries’ ‘world views, agendas and pre-defined 
objectives’ (Buss, 2011). Instead, ‘horizontal partnership’ is Brazil’s 
preferred terminology to indicate the wish to draw on principles of non-
interference and mutual advantage. Brazilian projects are also claimed to 
promote ‘structural cooperation in health’, a concept defined by some 
as building local capacity for development (Buss, 2011). It begins from 
the premise that health cooperation should focus on integrating human 
resources for health and institutional development, developing local 
capacity to avoid dependency from foreign expertise and promoting 
internal collaboration between local health institutions to elaborate 
their own health system development agenda. 
 As for the relation between national business interests and cooperation 
goals, Brazilian cooperation in health openly claims to be inspired by 
the concept of the ‘health-industrial complex for health development’, 
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according to which individual countries need to invest in the national 
health care industry and R&D capacity if they want to develop their 
health systems (see also Chapter 9). Such an emphasis on self-sufficiency 
is also aimed at avoiding costly dependency on foreign health care tech-
nologies (Gadelha, 2006). This approach happens to be particularly rele-
vant for the pharmaceutical and biotechnology business in Brazil, as, 
besides being worth approximately US$24.5 billion in 2012, these two 
sectors are considered to be instrumental in the implementation of the 
Brazilian Unified Healthcare System’s objectives of free and equitable 
access to health care services (Gadelha et al., 2013). Brazil’s position on 
HIV/AIDS drugs appears in line with its support for strong government 
involvement in the provision of health care services, underpinned by 
a constitutional framework that establishes a universal citizen right 
to health and places a duty of health care provision on the state. The 
growing roles of the Brazil’s Ministry of Health research and training 
agency,  Fiocruz , and its pharmaceutical arm,  Farmanguinhos , influential 
government institutions behind the development of the ARV industry 
in Brazil as well as in the factory project in Mozambique, are exemplifi-
cations of the strength of this paradigm of state-led health development 
(see Chapter 9). 
 Local production of pharmaceuticals: issues raised 
by the case study 
 In contrast to the experiences described in other chapters, the Maputo 
factory story provides a case study of an attempt to kick-start, through 
an innovative South-South partnership, pharmaceutical production in 
a country that previously had none. Our narrative of development and 
implementation of the project has shown the key role of the innovative 
South-South collaboration for the nascent pharmaceutical industry in 
Mozambique in terms of both financial subsidy and technical support. 
However, while the technical collaboration with Brazil remains highly 
positive, the link to health markets in Mozambique seems to have been 
a major problem, as the health-industry link so fundamental in the 
Brazilian pharmaceutical development experience seems to have worked 
less well here, at least for these early years. 
 The experience of the Brazil-Mozambique collaboration details the 
challenges of starting up such a complex enterprise from scratch, in an 
environment often lacking the basic infrastructural pillars for industry 
development. Human resources were identified as the single most 
important bottleneck for SMM development. As the majority of the 
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staff recruited locally had to be sent for training abroad, some of those 
employed have been poached by competing businesses in wholesaling 
and retailing, and highly specialized positions in the factory are still 
covered by expatriate staff. Although personnel with middle-manage-
ment skills should be already supplied by the local labour market, expe-
rienced executives with a track record of management in comparable 
industries are acutely lacking in Mozambique, given the country’s rela-
tively recent history of industrial development. 
 Mozambique’s particular industrial environment was recognized 
as another factor hampering the development of the pharmaceutical 
factory. In comparison to other African countries with a more established 
industry, Mozambique seems to be lacking a critical mass of suppliers, 
products and services needed for the development of a competitive 
pharmaceutical business. All the primary products needed for Maputo 
factory’s manufacturing are, up to now, imported from Brazil; all the 
basic maintenance and technical services are contracted to South African 
firms, and resorting to lower cost Indian and Chinese equipment has 
not been an option, given the limited equipment maintenance services 
provided by such suppliers in Mozambique. 
 Strengthening the government’s current quality control of pharma-
ceutical manufacturing processes and final products is needed, as this 
was also reported to be a hurdle for the long-term development of phar-
maceutical manufacturing in Mozambique. A lack of quality regulation 
 de facto allows competitors to employ cheaper substandard machinery 
in pharmaceutical production and produce substandard – and, crucially, 
cheaper – generic products. The factory’s case study shows that lack 
of effective quality regulation ends up benefitting those importers of 
non-branded generics for whom an ability to cut costs and offer wildly 
discounted generics represents the core of their market strategy in 
Mozambique. 
 This experience, however, also identifies a path to local industry 
development based on foreign assistance but also on national govern-
ments’ willingness to support local procurement of drugs (Russo and 
Banda, forthcoming). As is already well known in those African coun-
tries with a more established pharmaceutical industry, this case study 
reaffirms that only through preferential pricing and reduced profit 
margins can local medicine production be competitive in Mozambique, 
but that the spill-over information-related benefits from local produc-
tion can be substantial for epidemiological surveillance as well as 
for governments’ price negotiations (Russo et al., 2014). However, a 
number of points of discussion are raised by this case study on the 
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feasibility, sustainability and opportunity of local pharmaceutical 
production in Africa. 
 At the time of writing, the factory’s sustainability after the likely end 
of Brazil’s support in 2017 remains an issue. Brazil’s original objective 
was to provide MISAU with enough production capacity to carry out its 
medicine policies; however, the GoM’s appointment of IGEPE, together 
with the conspicuous absence of references to the factory in MISAU’s 
policy documents, seem to signal a more pronounced interest in the 
factory’s contribution to the country’s industrial assets rather than to 
its public health goals. To this respect, the GoM will have to decide 
whether it is still in its interest to keep the factory as a public enterprise, 
or to attempt a privatization with a degree of public sector involvement, 
in the way similar experiences developed in Uganda and South Africa 
(Rajagopal, 2013; World News, 2013). 
 Finally, this case study raises questions about the suitability of foreign 
health policy and production models to the African context. If Brazil’s 
original plan was to help Mozambique to replicate its own domestic 
experience in the AIDS fight and in pharmaceutical production, the 
implementation of this factory project exposed Brazil’s limited famili-
arity with the development cooperation conundrum, but also the rele-
vance of the differences between the two contexts (Russo et al., 2014). If 
some of the holdups in the project could be attributed to the relative lack 
of experience of Brazilian civil servants borrowed from their domestic 
duties to implement a cooperation project in the African continent, 
this case study probably shows that solutions that have proved effective 
elsewhere are hard to replicate in Mozambique for more than just one 
reason. 
 First, there is evidence from this experience that MISAU’s engagement 
with the project and enthusiasm for using the factory as an implementa-
tion tool for its own national drug policy has not been the same as that 
which motivated the creation of public pharmaceutical laboratories in 
Brazil in the past decades (Russo et al., 2014; Flynn, 2010). Second, in 
stark contrast to what happens in the Brazilian pharmaceutical market, 
the majority of medicines in Mozambique are imported and paid for by 
the international community, so it is easy to understand why the govern-
ment of Mozambique failed to see short-term gains in acquiring national 
production capacity and paying for something – ARV drugs –already 
provided for free. Finally, the human capital and manufacturing envi-
ronment fundamentals that made possible the development of the 
pharmaceutical industry in Brazil are, in all likelihood, not yet in place 
in Mozambique. As a result, setting up a factory project already tested 
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back home became highly cumbersome in a context where lack of skills, 
funds and services is the norm rather than the exception (Cabral, Russo 
and Weinstock, 2014). 
 Conclusion 
 Contrasting with other chapters in Part I that discuss very different 
experiences in African countries with a more established pharmaceu-
tical industry, the present chapter has presented an original experience 
of developing local manufacturing from scratch through collaboration 
between two national governments. By describing the decade-long 
process through which Brazil and Mozambique cooperated to set up 
 Sociedade  Moçambicana de  Medicamentos in Maputo, we aimed to illustrate 
the complexity of shoring up such an ambitious development coopera-
tion project. Our analysis suggests that national and regional demand 
may justify SMM’s production of ARVs and other generic drugs, but that 
public purchase of drugs remains essential to guarantee the sustaina-
bility of the business. We have also highlighted the differences between 
the two settings, Mozambique and Brazil, and have drawn attention to 
the possible risks involved in putting emphasis on the development of 
an enterprise without linking up adequately with local pharmaceutical 
markets. We believe that such an experience offers an insight into the 
complexities of developing pharmaceutical manufacturing operations in 
Sub-Saharan Africa, and into the options that the international commu-
nity has to support it. The hope is that this will contribute to advancing 
the debate on local pharmaceutical manufacturing and on paths to its 
development. 
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